DOCSLIB.ORG

Antitumor Activity of Trovafloxacin in an Animal Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antitumor Activity of Trovafloxacin in an Animal Model in vivo 19: 269-276 (2005) Antitumor Activity of Trovafloxacin in an Animal Model HARAGOPAL THADEPALLI1, FRANK SALEM1, SEE KEAN CHUAH1 and SASTRY GOLLAPUDI1,2 1Charles R. Drew University, School of Medicine, Los Angeles, CA, 90059; 2University of California, Irvine, CA 92697, U.S.A. Abstract. Quinolone antibiotics come close to being ideal showed antitumor activity and it was found that these chemotherapeutic agents in that they are administered orally, are quinolones had two halogens at C-6, C-8 and N-1 cyclopropyl concentrated in cells and tissue, are readily available, relatively (not methyl or ethyl) subtituents on their chemical structures. safe and exhibit increased activity against both bacteria and Previously, we have reported that certain quinolones possess tumor cells both in vitro and in vivo. Our objective was to chemosensitizing activity and they reverse multidrug resistance evaluate the in vivo activity of trovafloxacin and ciprofloxacin in cancer cells (9,10). Furthermore, quinolones appear to have against murine leukemic cells in neutropenic mice with lung immunopotentiating properties (11, 12). Clearly these infection due to Klebsiella pneumoniae. The results showed that properties of quinolones are relevant to their therapeutic both trovafloxacin and ciprofloxacin were effective in clearing efficacy against infections associated with cancer. lung infection. However, trovafloxacin, but not ciprofloxacin, Trovafloxacin is a trifluoroquinolone that is effective against was effective in preventing metastasis of leukemia cells to the various aerobic and anaerobic gram-positive and gram-negative lungs and other tissue and in prolonging the survival of mice. organisms (see ref in 13). We recently reported that trovafloxacin was as effective as ciprofloxacin in clearing An antimicrobial agent that is active against both gram-negative Klebsiella pneumoniae lung infection in mice (13). However, in and gram-positive aerobic and anaerobic bacteria can be used tumor-bearing mice, trovafloxacin was found to be more as a single antibiotic for prophylaxis as well as treatment of effective in clearing the K. pneumoniae infection. This could not bacterial superinfections in cancer patients receiving be explained by the antimicrobial activity of these quinolones chemotherapy. Obviously, if such an agent is also effective in because the organism was equally susceptible to both preventing the growth of tumor cells, it is a double bonus. trovafloxacin and ciprofloxacin. In vitro evaluation of these Fluoroquinolones are inhibitors of prokaryotic DNA gyrase, a quinolones showed that trovafloxacin (but not ciprofloxacin) DNA topoisomerase. The quinolone antimicrobials share was very effective in inhibiting the growth of P388 murine structural features with flavonoid anticancer agents (1-4). leukemia cells (14). The purpose of this study was to examine Several quinolone derivatives were observed to inhibit the effect trovafloxacin and ciprofloxacin might have on the eukaryotic cell growth in vitro (5-8). Yamashita et al. (7) resolution of invasive cancer disease in the above animal model. evaluated several quinolones for their direct antitumor activity in the murine leukemia P388 model. They showed that many Materials and Methods antimicrobial quinolones at low concentrations do not induce mammalian topoisomerase II-mediated cleavage of DNA and Animals. Six to 8 week-old male DBA/2 mice were used. do not exhibit antitumor activity. However, 12 quinolones Tumor cells. P388 murine leukemia cells were maintained in vitro as a suspension culture in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 Ìg/ml penicillin and 50 Ìg/ml streptomycin. Correspondence to: Haragopal Thadepalli, MD, Professor of Medicine and Pathology, Division of Geriatrics/Gerontology, Tumor induction and therapy. One million P388 murine leukemia Department of Internal Medicine, Charles Drew University of cells were injected into the peritoneal cavity of the mice. The mice Medicine and Science, 1731 East 120th Street, Los Angeles, CA were treated with daunorubicin (DNR 10 Ìg/kg/dose, once a day) 90059, U.S.A. Tel: (323) 563-4822, Fax: (323) 563-9393, e-mail: for 3 days. DNR was administered intraperitoneally. Chemotherapy [email protected] was initiated 24 hours after the introduction of tumor cells. ∫ey Words: Trovafloxacin, antitumor activity, quinolone antibiotics, Antimicrobial chemotherapy. Therapy was initiated on the fourth ciprofloxacin. day. The mice were treated with alatrovafloxacin (CP-116, 517-27), 0258-851X/2005 $2.00+.40 269 in vivo 19: 269-276 (2005) Table I. Survival of tumor-bearing mice treated with trovaflocacin, Table II. Survival of tumor-bearing mice treated with trovaflocacin, ciprofloxacin, or Daunorubicin (DNR) (First trial). ciprofloxacin, or Daunorubicin (DNR) (Second trial). Tumor-bearing Survivors/ Survival Number of Tumor-bearing Survivors/ Survival Number of mice treated with total rate survivors mice treated with total rate survivors number (%) with sterile number (%) with sterile of mice cultures of mice cultures per group (% cure ) per group (% cure ) NO DNR/Saline 0/11 0 0(0) NO DNR/Saline 1/20 5 0(0) NO DNR/ Trovafloxacin 1/11 9 1(100) NO DNR/ Trovafloxacin 9/24 38 9 (100) NO DNR/Ciprofloxacin 2/11 18 2(100) DNR/Saline 1/17 6 0 (0) DNR/Saline 1/11 9 0 (0) DNR/Trovafloxacin 14/20 70 13(93) DNR/Trovafloxacin 10/11 91 10 (100) DNR/Ciprofloxacin 5/19 26 3( 60) DNR/Ciprofloxacin 2/11 18 1 (50) No DNR/Trovafloxacin/rGCSF 10/25 40 2 (20) No DNR/Trovafloxacin/rGCSF 6/12 50 5 (83) DNR/Trovafloxacin/rGCSF 12/17 71 12(100) DNR/Trovafloxacin/rGCSF 10/12 83 10 (100) DNR/Ciprofloxacin/rGCSF 7/17 41 7 (100) a prodrug of trovafloxacin (Pfizer Inc., Groton, CT, USA) or Autopsy. At autopsy, the tumor was found metastatic to the alatrovafloxacin plus GCSF. It was compared with another liver, spleen and mostly the lungs. In control animals, gross quinolone ciprofloxacin alone and ciprofloxacin with the rGCSF. sections of the solid organs showed metastasis. The lung was Trovafloxacin, ciprofloxacin and GCSF were given intraperitoneally leathery hard and grossly consolidated with minimal air in three times a day at 4-hour intervals. The dosage of alatrovafloxacin and ciprofloxacin were 30 mg/kg/dose and 20 controls as well as animals treated with DNR with or mg/kg/dose, respectively. The prodrug alatrovafloxacin is readily without ciprofloxacin, as well as trovafloxacin alone without soluble in water at neutral pH and 30 mg of this prodrug is DNR. On the other hand, the majority of DNR-pretreated equivalent to 20 mg of the active trovafloxacin compound (15). The animals that received trovafloxacin therapy had no grossly dosage of GCSF was 10 Ìg/kg/dose. Mice that were treated without detectable metastatic deposits in the solid organs and the any antibiotic (only saline) were used as controls. lungs were spongy and aerated. In trial I (Table I), the survival rate without any antibiotic Quantitative analysis. Antibiotic therapy was given for 7 days. One to 2 days after the distribution of antibiotics, all mice were sacrificed by (saline injection) was 0% and it did not improve on DNR cervical dislocation. At autopsy, lungs were removed aseptically and therapy. On ciprofloxacin therapy, the survival rate was 18% transferred to 10% formalin. They were later embedded in paraffin without DNR and it was 18% with the addition of DNR. On blocks, sectioned and stained with hematoxylin/eosin and examined the other hand, on trovafloxacin the survival rate jumped for the spread of tumor cells in the lungs. Infiltration of malignant from 9% to 91%, a ten-fold increased survival when DNR cells into the lung tissue was classified as 0 to 3+ arbitrarily. No was added. Upon addition of rGCSF, the survival rate was cells=0, infiltration into bronchus or blood vessel 3+, readily 83%, i.e., rGCSF therapy had no additional benefit. detectable in every field 2+, occasional malignant cells seen after searching more than four high power fields=1+. No malignant cells In trial II (Table II), this result was reproducible on seen after searching four high powerfields=0+. repeat experiment. Briefly, the survival rate was 5% to 6% on saline with or without DNR and 9% to 26% on Results ciprofloxacin with or without DNR. The survival rate on trovafloxacin was 38% without DNR, Survival. Each experiment was done twice to verify the which improved to 70% when DNR therapy was added. reproducibility of results. Each experiment was done with or Addition of rGCSF and DNR therapy to ciprofloxacin had without the addition of daunorubicin (DNR) and with or minimal effect with a cure rate of 41% (26% with DNR alone), without the addition of rGCSF. The cumulative mortality whereas trovafloxacin plus DNR plus rGCSF had a 71% cure without any therapy was 50% on day 10. After the inoculation rate. of tumor cells, there was a cumulative mortality of 50% In summary, there was 28% survival without any quinolone. without any therapy on day 10 and it was 12 days with DNR The survival rate on ciprofloxacin plus DNR was 23%, which and ciprofloxacin therapy without the addition of DNR. The improved to 41% on addition of rGCSF. On the other hand, 50% cumulative mortality on trovafloxacin without DNR alatrovafloxacin therapy had a survival rate of 77% to 80% occurred by the 12th day, whereas on DNR + trovafloxacin and it was unmodified (75% survival) when rGCSF was the survival was about 80% on day 15, which was not added. Thus, trovafloxacin exhibited superior efficacy to influenced by the addition of GCSF. ciprofloxacin in protecting these animals from cancer. 270 Thadepalli et al: Antitumor Activity of Trovafloxacin in an Animal Model Tissue concentration of trovafloxacin. Following 20 mg/kg of In our study, ciprofloxacin exhibited low antitumor activity intraperitoneal injection, the trovafloxacin level in the lung in the P388 leukemia animal model with nearly 80% mortality (17.5 Ìg/g) was more than three times the serum level (5.16 with or without the addition of DNR.
Load more

Recommended publications
  • Fluoroquinolones in the Management of Acute Lower Respiratory Infection
    Thorax 2000;55:83–85 83 Occasional review Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults Peter J Moss, Roger G Finch Lower respiratory tract infections (LRTI) are ing for up to 40% of isolates in Spain19 and 33% the leading infectious cause of death in most in the United States.20 In England and Wales developed countries; community acquired the prevalence is lower; in the first quarter of pneumonia (CAP) and acute exacerbations of 1999 6.5% of blood/cerebrospinal fluid isolates chronic bronchitis (AECB) are responsible for were reported to the Public Health Laboratory the bulk of the adult morbidity. Until recently Service as showing intermediate sensitivity or quinolone antibiotics were not recommended resistance (D Livermore, personal communi- for the routine treatment of these infections.1–3 cation). Pneumococcal resistance to penicillin Neither ciprofloxacin nor ofloxacin have ad- is not specifically linked to quinolone resist- equate activity against Streptococcus pneumoniae ance and, in general, penicillin resistant in vitro, and life threatening invasive pneumo- pneumococci are sensitive to the newer coccal disease has been reported in patients fluoroquinolones.11 21 treated for respiratory tract infections with Resistance to ciprofloxacin develops rela- these drugs.4–6 The development of new fluoro- tively easily in both S pneumoniae and H influ- quinolone agents with increased activity enzae, requiring only a single mutation in the against Gram positive organisms, combined parC gene.22 23 Other quinolones such as with concerns about increasing microbial sparfloxacin and clinafloxacin require two resistance to â-lactam agents, has prompted a mutations in the parC and gyrA genes.11 23 re-evaluation of the use of quinolones in LRTI.
    [Show full text]
  • FLUOROQUINOLONES: from Structure to Activity and Toxicity
    FLUOROQUINOLONES: from structure to activity and toxicity F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université Catholique de Louvain, Brussels, Belgium SBIMC / BVIKM www.sbimc.org - www.bvikm.org www.md.ucl.ac.be/facm www.isap.org soon... Mechanism of action of fluoroquinolones: the basics... PORIN DNA Topo DNA gyrase isomerase Gram (-) Gram (+) 2 key enzymes in DNA replication: DNA gyrase topoisomerase IV bacterial DNA is supercoiled Ternary complex DNA - enzyme - fluoroquinolone DNA GYRASE catalytic subunits COVALENTLY CLOSED CIRCULAR DNA FLUOROQUINOLONES: DNA GYRASE ATP binding subunits 4 stacked molecules (Shen, in Quinolone Antimicrobial Agents, 1993) Resistance to fluoroquinolones: the basics decreased efflux pump permeability DNA mutation of DNA gyrase Topo isomerase the enzymes Gram (-) Gram (+) Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ? R5 O R COOH 6 R7 X8 N R1 Don’t panic, we will travel together…. Chemistry and Activity This is where all begins... The pharmacophore common to all fluoroquinolones BINDING TO DNA R5 O O R C 6 - BINDING TO O BINDING TO THE ENZYME THE ENZYME R7 X8 N R1 AUTO-ASSEMBLING DOMAIN (for stacking) From chloroquine to nalidixic acid... nalidixic acid N CH3 O O HN CH 3 C - O chloroquine CH N N Cl N 3 C2H5 1939 O O C O- 1962 Cl N 1958 C2H5 7-chloroquinoline (synthesis intermediate found to display antibacterial activity) Nalidixic acid * a • typical chemical features of O O fluoroquinolones (a, b, c) BUT a naphthridone C - O- b (N at position 8: ) H C N N 3 • limited usefulness as drug C H 2 5 • narrow antibacterial spectrum c (Enterobacteriaceae only) • short half-life (1.5h) • high protein binding (90%) * Belg.
    [Show full text]
  • TROVAN® Tablets(Trovafloxacin Mesylate)
    TROVAN- trovafloxacin mesylate tablet, film coated TROVAN- trovafloxacin mesylate injection, solution, concentrate Roerig ---------- TROVAN® Tablets (trovafloxacin mesylate) TROVAN® I.V. (alatrofloxacin mesylate injection) For Intravenous Infusion TROVAN® HAS BEEN ASSOCIATED WITH SERIOUS LIVER INJURY LEADING TO LIVER TRANSPLANTATION AND/OR DEATH. TROVAN-ASSOCIATED LIVER INJURY HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS LIVER INJURY. LIVER INJURY HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE- EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE- OR LIMB-THREATENING INFECTIONS WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE. (SEE WARNINGS.) TROVAN is available as TROVAN Tablets (trovafloxacin mesylate) for oral administration and as TROVAN I.V. (alatrofloxacin mesylate injection), a prodrug of trovafloxacin, for intravenous administration. DESCRIPTION TROVAN Tablets TROVAN Tablets contain trovafloxacin mesylate, a synthetic broad-spectrum antibacterial agent for oral administration. Chemically, trovafloxacin mesylate, a fluoronaphthyridone related to the fluoroquinolone antibacterials, is (1α, 5α, 6α)-7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4- difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, monomethanesulfonate. Trovafloxacin mesylate differs from other quinolone derivatives by having a 1,8-naphthyridine nucleus. The chemical structure is: Its empirical formula is C20H15F3N4O3•CH3SO3H and its molecular weight is 512.46. Trovafloxacin mesylate is a white to off-white powder.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Pharmacokinetic Drug Interactions of Antimicrobial Drugs: a Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
    Pharmaceutics 2011, 3, 865-913; doi:10.3390/pharmaceutics3040865 OPEN ACCESS Pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Review Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams Mathieu S. Bolhuis *, Prashant N. Panday, Arianna D. Pranger, Jos G. W. Kosterink and Jan-Willem C. Alffenaar Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; E-Mails: [email protected] (P.N.P.); [email protected] (A.D.P.); [email protected] (J.G.W.K.); [email protected] (J.-W.C.A.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +31-50-361-4071; Fax: +31-50-361-4078 Received: 15 October 2011; in revised form: 26 October 2011 / Accepted: 9 November 2011 / Published: 18 November 2011 Abstract: Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions. These drug interactions are a major concern in clinical practice as they may have an effect on efficacy and toxicity. This article provides an overview of all published pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, focusing on systematic research. We describe drug-food and drug-drug interaction studies in humans, affecting antimicrobial drugs as well as concomitantly administered drugs. Since knowledge about mechanisms is of paramount importance for adequate management of drug interactions, the most plausible underlying mechanism of the drug interaction is provided when available.
    [Show full text]
  • Inhibitory Effects of Fluoroquinolone Antibiotics on Babesia Divergens and Babesia Microti, Blood Parasites of Veterinary and Zoonotic Importance
    Journal name: Infection and Drug Resistance Article Designation: Original Research Year: 2018 Volume: 11 Infection and Drug Resistance Dovepress Running head verso: Rizk et al Running head recto: Effects of fluoroquinolones on Babesia parasites open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IDR.S159519 Open Access Full Text Article ORIGINAL RESEARCH Inhibitory effects of fluoroquinolone antibiotics on Babesia divergens and Babesia microti, blood parasites of veterinary and zoonotic importance Mohamed Abdo Rizk1,2 Aim: This study aimed to evaluate the inhibitory effects of fluoroquinolone antibiotics, includ- Mahmoud AbouLaila3 ing enrofloxacin, enoxacin, trovafloxacin, norfloxacin, and ofloxacin, on the in vitro and in vivo Shimaa Abd El-Salam growth of Babesia divergens and Babesia microti parasites, respectively. El-Sayed1,4 Materials and methods: The in vitro and in vivo inhibitory effects of fluoroquinolone Azirwan Guswanto1,5 antibiotics against B. divergens and B. microti, respectively were evaluated using fluorescence- based assay. Additionally, combination therapies of highly effective fluoroquinolone antibiotics Naoaki Yokoyama1 (enrofloxacin, enoxacin, and trovafloxacin) with diminazene aceturate, luteolin, or pyronaridine Ikuo Igarashi1 tetraphosphate were tested on the in vitro cultures of B. divergens. 1 National Research Center for Results: Enrofloxacin, trovafloxacin, and enoxacin were the most effective fluoroquinolones Protozoan Diseases, Obihiro University of Agriculture and against the in vitro growth of B. divergens, followed by norfloxacin and ofloxacin. Further- Veterinary Medicine, Inada-Cho, more, a combination of enoxacin or trovafloxacin with either diminazene aceturate, luteolin, Obihiro, Hokkaido, Japan; or pyronaridine tetraphosphate significantly enhanced the inhibitory effect on the growth ofB. 2Department of Internal Medicine and Infectious Diseases, Faculty of divergens in in vitro cultures.
    [Show full text]
  • Antibiotic Prescribing – Quality Indicators
    Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 Antibiotic prescribing – quality indicators P1460 Methods: Medical records from all patients with positive blood Is self-medication with antibiotics in Europe cultures in 2001 were analysed retrospectively. Factors driven by prescribed use? predisposing to infections, results of blood cultures, antibiotic use, and outcome were recorded. L. Grigoryan, F.M. Haaijer-Ruskamp, J.G.M. Burgerhof, Results: The antibiotic use in 226 episodes of true bacteraemia J.E. Degener, R. Deschepper, D. Monnet, A. Di Matteo, were analysed. According to guidelines empirical antibiotic ˚ and the SAR E.A. Scicluna, A. Bara, C. Stalsby Lundborg, J. Birkin treatment should be adjusted in 166 episodes. Antibiotic use was group adjusted in 146 (88%) of these 166 episodes, which led to a Objectives: The occurrence of self-medication with antibiotics narrowing of therapy in 118 (80%) episodes. Compared to has been described in the US and Europe, a possible empirical therapy there was a 22% reduction in the number of contributing factor to increased antibiotic resistance. An antibiotics. Adjustment of therapy was more often performed in important reason for using self-medication can be past Gram-negative bacteraemia and polymicrobial cultures than in experience with antibiotics prescribed by health professionals. Gram-positive bacteraemia. In bacteraemia caused by We investigated whether self-medication in Europe follows the ampicillin-resistant E. coli, ampicillin was mostly replaced by same pattern as prescribed use. ciprofloxacin. The cost for 7 days adjusted therapy was 19800 Methods: A population survey was conducted in: North and EUR (23%) less than for 7 days of empirical therapy.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • 2000 Dialysis of Drugs
    2000 Dialysis of Drugs PROVIDED AS AN EDUCATIONAL SERVICE BY AMGEN INC. I 2000 DIAL Dialysis of Drugs YSIS OF DRUGS Curtis A. Johnson, PharmD Member, Board of Directors Nephrology Pharmacy Associates Ann Arbor, Michigan and Professor of Pharmacy and Medicine University of Wisconsin-Madison Madison, Wisconsin William D. Simmons, RPh Senior Clinical Pharmacist Department of Pharmacy University of Wisconsin Hospital and Clinics Madison, Wisconsin SEE DISCLAIMER REGARDING USE OF THIS POCKET BOOK DISCLAIMER—These Dialysis of Drugs guidelines are offered as a general summary of information for pharmacists and other medical professionals. Inappropriate administration of drugs may involve serious medical risks to the patient which can only be identified by medical professionals. Depending on the circumstances, the risks can be serious and can include severe injury, including death. These guidelines cannot identify medical risks specific to an individual patient or recommend patient treatment. These guidelines are not to be used as a substitute for professional training. The absence of typographical errors is not guaranteed. Use of these guidelines indicates acknowledgement that neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. will be responsible for any loss or injury, including death, sustained in connection with or as a result of the use of these guidelines. Readers should consult the complete information available in the package insert for each agent indicated before prescribing medications. Guides such as this one can only draw from information available as of the date of publication. Neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. is under any obligation to update information contained herein. Future medical advances or product information may affect or change the information provided.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]